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Fifty-two samples of pediatric low-grade glioma (48 primary, 4 recurrent) were analyzed for BRAF
copy number variation (digital PCR analysis, CopyCaller) and point mutations of BRAF V600E, and
exon 5 Q209 in GNAQ, and GNA11, using the MALDI-TOF mass spectrometer with validation by direct
sequencing. An increased BRAF copy number was found in 18/47 primary samples tested; 15 of them
(83.3%) were pilocytic astrocytomas. A BRAFmutation was found in 3/48 primary tumors, all with a
normal BRAF copy number and no GNAQ mutation. One sample had a GNAQ209 mutation
(Q209P626) with a normal BRAF gene; none of the tumors had a GNA11Q209 mutation. Recurrent
or progressive tumors, analyzed in four patients, had the same molecular genotype as their primary.
Increased BRAF copy number and activating BRAFmutations may be involved in the development of
low-grade glioma via overactivation of the Ras/Raf pathway. This is the ﬁrst report of a mutation in
GNAQ209 in pediatric low-grade glioma. Understanding the molecular mechanisms underlying gli-
oma initiation and growth may assist in the development of targeted therapies.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Brain tumors are themost commonsolid tumors in children,with
a prevalence of 2.4 per 100000 to 4 per 100000. More than 50% are
low-grade (I–II) gliomas originating from glial cells, most often
astrocytes [1]. TheWorld Health Organization (WHO) distinguishes
low-grade from high-grade (III–IV) gliomas by their less aggressive
biological behavior and better response to treatment. Among the
various types of low-grade gliomas, pilocytic astrocytomas account
for23%of all central nervous systemtumors in children. Theﬁrst line
of treatment of low-grade glioma is surgical resection. However,
tumors located in the diencephalon, brain stem, or optic pathways
cannot be completely resected [2] and require chemotherapy or
radiation, which may have severe side effects, such as cognitive
impairment, vascular injury, and secondary malignancies. Even
surgery alone can be associatedwithmajor neurological and behav-
ioral morbidities and recurrence. The reported 10-year survival rateal Societies. Published by Elsevier
arch Laboratory, Felsenstein
va 49 100, Israel. Fax: +972 3
rg-Cohen).is more than 95% for pilocytic astrocytoma grade I [3] but much
lower for grade II [4].
Relatively little is known about the molecular changes that
promote the formation or growth of low-grade gliomas in children.
Research in glioma biology points to a major role of the Ras/Raf/
MEK/ERK mitogen-activated protein kinase (MAPK) pathway,
which is pivotal to the transduction of mitogenic stimuli from acti-
vated growth factor receptors during regulation of cell prolifera-
tion, survival, and differentiation [5]. Serine/threonine-protein
kinase B-raf, a member of the Raf family of kinases, serves as a
downstream effector in the MAPK pathway. Recently, genetic stud-
ies of low-grade glioma have focused on gains in band 7q34 [6–11]
which includes part of the BRAF gene locus that encodes the kinase
domain [6]. The Ras/Raf pathway may also be activated by onco-
genic mutations of the RAF gene itself, such as the substitution of
glutamic acid for valine at amino acid 600 (V600E). However, the
low rate at which such mutations have been found in pediatric
low-grade gliomas (3–10%) [6–11], suggests that othermechanisms
may be involved in their development.
In the RAS pathway, the guanine nucleotide-binding protein
(Gq) subunit alpha, a protein encoded by the GNAQ gene, may also
play a role in tumorigenesis. Genetic, biochemical, and biological
analyses have shown that GNAQ behaves like a human oncogene.B.V. Open access under CC BY-NC-ND license.
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Ras-like domain and led to constitutive activation [12,13]. The glu-
tamine at codon 209 of the GNAQ gene corresponds to residue 61 of
the RAS gene and is essential for guanosine triphosphate (GTP)
hydrolysis [13]. In other Ras family members, mutations at this site
caused loss of GTPase activity [13]. It is noteworthy that exon 5 of
GNA11, another Gq family member, contains an equivalent residue
to Q209 of GNAQ. BRAF and GNAQmutations are mutually exclusive
in several tumors, such as uveal melanoma [14]. The prevalence of
GNAQ or GNA11 mutations in pediatric low-grade gliomas has not
yet been investigated.
The aim of the present study was to determine the occurrence
of BRAF, GNAQ, and GNA11 mutations in pediatric low-grade gli-
oma, primary and recurrent, and to analyze variations in copy
number of the BRAF oncogene which identify gains in band 7q34.
2. Results
2.1. Clinical data
Fifty-two samples of pediatric low-grade glioma (WHO I–II)
were collected from 48 children operated in 1995–2000 (including
material from second operations) at Schneider Children’s Medical
Center of Israel. Thirteen patients received chemotherapy before
(one patient) or after surgery (12), and three also received radia-
tion therapy. Table 2 summarizes the relevant clinical data. Mean
patient age was 8.5 years (range, 1 month to 18 years), and the fe-
male to male ratio was 1.08. The medical histories revealed that
four patients had neuroﬁbromatosis type 1 (patient nos. 5, 8, 12
and 35, Table 2). Two patients had tuberous sclerosis (nos. 47,
48), and 1 patient had Lhermitte-Duclos disease (no. 32).
Thirty-one tumors (64.6%) were located supratentorially and 17
infratentorially, 15 in the posterior fossa and two in the brain stem.
The molecular analysis was performed on the material from the
biopsy study of the primary or from a sample at recurrent surgery
(n = 4, nos. 4, 16, 37, 44, Table 2). The second surgical sample was
analyzed in these four patients since in two the tumors had been
technically undeﬁned at the ﬁrst biopsy (nos. 16, 37), in one there
was tumor progression (no. 4) and in one with true tumor recur-
rence (no. 44).
The breakdown by type of tumor was as follows: grade I glioma,
41 samples – pilocytic astrocytoma (n = 31), ganglioglioma (n = 7),
subependymal giant cell astrocytoma (n = 2), and gangliocytoma
(n = 1), grade II gliomas, total 7 samples – ﬁbrillary astrocytoma
(n = 2), pleomorphic xanthoastrocytoma (n = 3), pilomyxoid astro-
cytoma (n = 1), and astroblastoma (n = 1). In one patient (no. 5,
Table 2), the primary diagnosis based on histologic biopsy study
at the ﬁrst surgery was pilocytic astrocytoma of the optic pathway,
whereas the diagnosis based on a sample from a third operation
was pilomyxoid astrocytoma (grade II).
The median duration of follow-up was 6 years (range, 6 months
to 22 years). Two patients died during follow-up (nos. 5, 44,
Table 2). Patient 5, who had neuroﬁbromatosis type 1, died of acute
myeloid leukemia which could have been secondary to prolonged
treatment with vincristine/carboplatin for her optic glioma (2
years from onset of treatment). Patient 44 died of malignant trans-
formation of a pleomorphic xanthoastrocytoma.Table 1
Primers used for validation of mutations by PCR test.
Gene Forward
BRAF V600E GGCACATCACTGAACATAATTATC
GNAQ209 TTTTCCCTAAGTTTGTAAGTAGTGC
GNA11Q209 CGCTGTGTCCTTTCAGGATG2.2. Molecular analysis
The results of the molecular analysis of the primary glioma
specimens (total 48) are summarized in Table 3. BRAF copy number
was analyzed in 47 samples; one sample (from patient no. 32)
failed technically due to a limited amount of DNA. An increased
BRAF copy number was noted in 18 of the 47 samples: three copies
in 14 samples, four copies in four samples. A BRAF mutation was
found in 3 of the 48 samples analyzed; a GNAQ209 mutation, in 1
of the 47 samples analyzed; and a GNA11 mutation, in none of
the 27 samples analyzed. All three samples with BRAF mutations
had a normal copy number (2), and none of the GNAQ-positive
samples harbored a BRAFmutation or abnormal number of BRAF al-
leles. All four recurrent tumors showed the same molecular geno-
type as their primary tumor (not shown in Table 3).
2.2.1. BRAF mutation
The V600E point mutation was identiﬁed in the BRAF gene in 3
of the 48 primary samples (6.3%) (Table 3), derived from one
patient each with pilocytic astrocytoma, ganglioglioma, and pleo-
morphic xanthoastrocytoma. Fig. 1 demonstrates the mutation in
exon 15 of the BRAF gene, in which the nucleotide thymine (T) is
replaced with adenine (A), leading to the translation of glutamic
acid instead of valine and, thereby, to overactivation of the Ras/
Raf cascade.
2.2.2. GNAQ209 and GNA11209 mutation
Sequencing of exon 5 of the GNAQ gene yielded one patient (no.
15, Table 3) with a mutation in codon 209, in which the nucleotide
adenine (A) is replaced with cytosine (C), causing loss of GTPase
activity and constitutive activation of the Ras cascade. The sample
was derived from a pilocytic astrocytoma. No Q209 mutations
were found in exon 5 of the GNA11 gene (Table 2).
2.2.3. BRAF copy number variation
Fig. 1 schematically summarizes the ﬁndings on quantitative
real-time PCR analysis of the BRAF gene in 47 patients. The results
are also shown in Table 3. More than two copies of the BRAF gene
were found in 18 patients (18/47; 38.3%) and two copies, in 29 pa-
tients (61.7%). Fifteen of the 18 samples with an increased copy
number (83.3%) were from pilocytic astrocytomas; the others were
derived from ganglioglioma, pilomyxoid astrocytoma, and pleo-
morphic xanthoastrocytoma (one each).
On analysis of the clinical factors, a higher median age was
noted for the patients with an increased copy number (9.5 years)
than for the patients with two copies only (8.5 years), but the dif-
ference was not statistically signiﬁcant. No signiﬁcant differences
by copy number (increased/normal) were found for sex (M/F),
tumor grade (I/II), number of operations (1/more), diagnosis of
neuroﬁbromatosis-1 (yes/no), need for chemotherapy (yes/no),
need for radiotherapy (yes/no), or mortality. The only statistically
signiﬁcant difference between the patients with and without an
increased BRAF copy number was location of the glioma: 62.5%
(10/16) of the infratentorial tumors had more than two copies of
the gene compared to 25.8% (8/31) of the supratentorial tumors
(P = 0.014).Reverse PCR product size
AGCATGATATCACAAAGGTACT 224bp
CCTCATTGTCTGACTCCACG 222bp
CCACCTCGTTGTCCGACT 150bp
Table 2
Clinical and demographic data of children with low-grade glioma.
Pt. no. Age at 1st op. (yr) M/F Diagnosis Tu. location 2nd op. MH Chemotherapy Radiotherapy Death
1 0.9 F PA OTG n n y n n
2 16.9 F PA chia–ht y n y n n
3 23.4 F PA OTG n n y n n
4⁄ 2 M PA chia–ht y n y y n
5 3 F PA chia–ht y NF-1 y n y
6 1.1 M PA chia–ht n n y n n
7 8.4 M PA chia–ht n n n n n
8 4.6 F PA OTG n NF-1 y n n
9 3.8 F PA chia–ht n n n n n
10 1.4 F PA chia–ht n n y n n
11 2.7 M PA PF y n y n n
12 10.11 M PA Temporal n NF-1 n n n
13 16.6 F PA PF n n n n n
14 16.1 M PA PF y n n n n
15 4.1 M PA PF n n n n n
16 12.7 F PA Temporal y n n n n
17 14.11 M PA Pineal n n n n n
18 5 F PA PF n n n n n
19 8.1 F PA PF n n n n n
20 2 F PA PF y n n n n
21 14.1 M PA PF y n n n n
22 6.1 F PA PF y n y n n
23 12.4 M PA PF n n n n n
24 1.9 M PA PF y n n n n
25 6.8 F PA Ventricle n n n n n
26 15 M PA PF n n n n n
27 2.5 M Astroblastoma Temporal y n n n n
28 14.3 F PA Temporal n n n n n
29 22 F FA Temporal n n n y n
30 7 F PA Ventricle y n n n n
31 11 F PA Brainstem n n y n n
32 2.2 M Gangliocytoma PF n LD n n n
33 0.1 F FA Temporal n n n n n
34 4.2 M PA Thalamus n n n n n
35 10.1 F PA PF n NF-1 y n n
36 3.5 M Pilomyxoid ast. PF n n n n n
37 17 F Ganglioglioma Brainstem y n n n n
38 3.1 M Ganglioglioma Temporal n n n n n
39 12.8 M Ganglioglioma Temporal n n n n n
40 14.4 M Ganglioglioma Occipital y n n n n
41 14 F Ganglioglioma Temporal y n n n n
42 14.2 F Ganglioglioma Temporal n n n n n
43 9.11 M Ganglioglioma Temporal n n n n n
44⁄ 12.11 F PXA Temporal y n y y y
45 11 F PXA Temporal y n n n n
46 14.9 F PXA Temporal y n n n n
47 5.8 M SEGA Ventricle n TS n n n
48 3.4 M SEGA Ventricle y TS n n n
MH = medical history; PA = pilocytic astrocytoma; FA = ﬁbrillary astrocytoma; PXA = pleomorphic xanthoastrocytoma; SEGA = subependymal giant cell astrocytoma;
OTG = optic tract glioma; chia-ht = chiasmatic–hypothalamic; PF = posterior fossa; NF-1 = neuroﬁbromatosis type 1; TS = tuberosclerosis; LD = Lhermitte–Duclos. ⁄Patients 4
and 44 multiple surgeries due to progression (4) and recurrence (44) (indicated by asterisk).
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This study investigated the molecular genotype of 48 samples of
primary low-grade gliomas and four samples of recurrent low-
grade gliomas from children. We searched speciﬁcally for genes
that are activated in the Ras/Raf (MAPK) signaling cascade (BRAF,
GNAQ and GNA11). The ﬁndings showed a low rate of BRAF muta-
tions (3/48) (one each in pilocytic astrocytoma, pleomorphic xan-
thoastrocytoma, and ganglioglioma), and only one case of a
GNAQ209 mutation (in a pilocytic astrocytoma). No GNA11 muta-
tions were found. However, an increased copy number of the BRAF
gene (3–4 copies) was detected in 18 patients (38.3%), compared to
29 patients (61.7%) with a normal number of copies.
These data are in line with previous studies of low-grade gli-
oma. Pﬁster et al. [6] found that 7q34 duplication was the mecha-
nism of BRAF activation in 53% of pilocytic astrocytomas, but was
negative in gangliogliomas and pleomorphic xanthoastrocytomas.
BRAF activation was conﬁrmed by the study of Jones et al. [9] byoverexpression of CCND1, a downstream target of the MAPK path-
way, and increased phosphorylation of extracellular signal-regu-
lated kinase (ERK) 1/2, an immediate downstream target of BRAF
when phosphorylated. The tandem 2-MB duplication at the 7q34
band described in this report in 66% of pilocytic astrocytomas,
led to an in-frame infusion gene incorporating the kinase domain
of the BRAF oncogene. Similarly, Forshew et al. [10] reported a high
frequency (64.8%) of copy number gain of about 1.9 MB at 7q34. In
all the pilocytic astrocytomas located in the posterior fossa, the
resulting fusion gene lacked the auto-inhibiting domain of BRAF.
Both Pﬁster et al. [6] and Jones et al. [9] showed an association
of 7q34 duplication with a supratentorial location (62% and 63%
of pilocytic astrocytomas, respectively). By contrast, in another
study by Bar et al. [7], of 25 sporadic pilocytic astrocytomas (20
infratentorial and ﬁve supratentorial), an increase in copy number
at the 7q34 locus was noted in 17 (68%), all located infratentorially.
In the present study, pilocytic astrocytoma was the pathologic
diagnosis in 15 of the 18 patients (83.3%) with more than two
Table 3
Results of molecular studies of pediatric low-grade gliomas.
Pt.
no.
BRAF copy
number
BRAF
mutation
GNA11
mutation
GNAQ
mutation
1 2 Positive NS neg
2 3 neg NS neg
3 2 neg NS neg
4 3 neg NS neg
5 3 neg NS neg
6 2 neg neg neg
7 2 neg neg neg
8 3 neg neg neg
9 4 neg neg neg
10 2 neg neg NS
11 2 neg NS neg
12 2 neg NS neg
13 3 neg NS neg
14 3 neg NS neg
15 2 neg NS Positive
16 2 neg neg neg
17 3 neg NS neg
18 3 neg NS neg
19 3 neg NS neg
20 2 neg neg neg
21 2 neg neg neg
22 3 neg neg neg
23 3 neg neg neg
24 2 neg NS neg
25 2 neg neg neg
26 2 neg neg neg
27 2 neg neg neg
28 2 neg neg neg
29 2 neg neg neg
30 3 neg NS neg
31 4 neg neg neg
32 NS neg neg neg
33 2 neg neg neg
34 2 neg neg neg
35 4 neg neg neg
36 3 neg neg neg
37 4 neg NS neg
38 2 neg neg neg
39 2 neg NS neg
40 2 neg neg neg
41 2 neg NS neg
42 2 Positive NS neg
43 2 neg neg neg
44 2 neg neg neg
45 2 Positive NS neg
46 3 neg neg neg
47 2 neg neg neg
48 2 neg neg neg
NS = not studied; neg = negative.
Fig. 1. (A) Schematic illustration of the variation in copy number of the BRAF gene on dig
in the number of copies is associated with overactivation of the Ras/Raf pathway. N = norm
the activating mutation V600E. The black arrow indicates replacement of nucleotide thy
132 Y. Laviv et al. / FEBS Open Bio 2 (2012) 129–134copies of BRAF. We identiﬁed both infratentorial and supratentorial
gain, but predominantly infratentorial (62.5%). Furthermore, the
incidence of increased copy number in all pilocytic astrocytoma
samples was 48.4%, lower than reported previously [6,7], suggest-
ing the involvement of other mechanisms.
Mutations in the BRAF gene and changes in its copy number
have also been described in lung and colon carcinoma, thyroid can-
cer, and melanoma [17–19]. Interestingly, administration of a drug
that inhibits the mutated activated BRAF gene reportedly led to
complete or partial regression of metastatic melanoma in humans
[20]. However, only a small proportion of the tumors in our study
and in other studies [9–11,21–24] had a BRAF600mutation, making
this drug unlikely to be effective in these cases.
This is the ﬁrst study to examine the GNAQ mutation in pediat-
ric low-grade glioma. Although very low in frequency, the GNAQ
gene might play a role in the early tumorigenesis of low-grade gli-
oma, as reported in uveal melanoma. In a large study, Lamba et al.
[25] sequenced exon 5 of the GNAQ and GNA11 genes in a panel of
922 tumors, including glioblastoma, gastrointestinal stromal
tumors, acute myeloid leukemia, blue nevi, melanoma, bladder,
breast, colorectal, lung, ovarian, pancreas, and thyroid carcinomas.
None of the tumor types showed GNAQ or GNA11mutations except
blue nevi (50%). In accordance with ﬁndings that BRAF and GNAQ
mutations are mutually exclusive [14], we found only BRAF muta-
tions in 6.3% of the samples, and the sole GNAQmutation in a sam-
ple that had wild-type BRAF gene. All tumors positive for either
BRAF or GNAQ mutations had a normal copy number of the BRAF
gene. There was no correlation of a positive ﬁnding with a medical
history of neuroﬁbromatosis-1 or tuberous sclerosis.
Interestingly, the four samples taken from secondary/recurrent
tumors showed identical molecular results. Given that all these
tumors were low grade with no metastases, they would not be
expected toundergomalignant transformationor genetic alteration.
Inhibitors of theMAPK pathway, such as AZD6244 and sorafenib,
have been approved for the treatment of several types of cancer
[20,26–28] and may be suitable for children with aggressive, recur-
rent, or unresectable tumors. This assumption is supported by the
ﬁnding of Pﬁster and colleagues [6] that pharmacological inhibition
of Ras/B-Raf/ERK signaling decreases the proliferation of low-grade
glioma cells in culture. However, as the MAPK pathway plays a cru-
cial role in tumor development, inhibiting its activity in the pediat-
ric brain could potentially lead to a wide range of side effects.
Therefore, therapies that speciﬁcally target the relevant oncogene
are preferable. Better understanding of the molecular basis of
low-grade glioma would increase the treatment options.ital PCR analysis (CopyCaller). The normal phenotype shows two copies. An increase
al pediatric brain tissue. (B) Sequencing of exon 15 in the BRAF gene demonstrating
mine (T) with adenine (A).
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children with low-grade glioma for mutations in three genes that
regulate the MAPK pathway, a crucial pathway in tumorigenesis.
Themain ﬁndingwas an increase in the copy number of BRAF; other
genetic changes causing this activation remain indeterminate. Addi-
tional pathways that are potentially involved in the formation and
growth of low-grade tumorigenesis need to be explored.4. Materials and methods
4.1. Clinical specimens
Archival samples of low-grade gliomas (WHO I–II) from pa-
tients aged less than 18 years were obtained from the Department
of Pathology, Rabin Medical Center. Only samples with sufﬁcient
excess parafﬁn-embedded or frozen tissue for analysis were in-
cluded. Tumor classiﬁcation and cellularity were reviewed by a
neuropathologist. Patients’ demographic and clinical data were
collected from the medical ﬁles. The procurement of the samples
and the study protocol were approved by the Institutional Review
Board of Rabin Medical Center and the National Genetics Review
Board of the Israel Ministry of Health.
4.2. DNA extraction
Forty-two formalin-ﬁxed, parafﬁn-embedded tissues and 10
frozen tissues were used for DNA isolation. In brief, hematoxylin-
eosin-stained 10-lm-section slides were reviewed by a patholo-
gist. Thereafter, areas with an estimated content of more than
75% tumor cells were separated by microdissection (no. 11 surgical
blade) from ﬁve consecutive 10-lm unstained parafﬁn-embedded
sections of each block. The tissues were deparafﬁnized and incu-
bated overnight in 1% sodium dodecyl sulfate (SDS) and proteinase
K 0.5 mg/ml. DNA was puriﬁed by phenol-chloroform extraction
and ethanol precipitation and dissolved in 50 ll of distilled water,
as previously described [15,16].
4.3. Mutation analysis
Oncogenic mutations in GNAQ (GNAQQ209, exon 5), GNA11
(GNA11Q209, exon 5) and BRAF (BRAFV600E, exon 15) were
analyzed with the chip-based matrix-assisted laser desorption
time-of-ﬂight (MALDI-TOF) mass spectrometer (Sequenom, San
Diego, CA). Speciﬁc primers ﬂanking the mutation sites and exten-
sion primers that bind adjacent to the mutation site were designed
with assay-design software (MassARRAY; Sequenom). After ampli-
ﬁcation of the region of interest, a primer extension reaction was
carried out which included sequence-speciﬁc hybridization and se-
quence-dependent termination, generating different products for
the mutated and wild-type alleles, each with a unique mass value.
The extension products were spotted onto silicon chips preloaded
with proprietary matrix (SpectroChip; Sequenom) and read by the
MALDI-TOF mass spectrometer.
4.4. Validation
The mutations were validated by direct sequencing of selected
samples. DNA was extracted using standard SDS/proteinase K
digestion followed by phenol-chloroform extraction and ethanol
precipitation. Each polymerase chain reaction (PCR) ampliﬁcation
was performed in a 50-ll reaction volume containing 150 ng of
sample DNA as a template. The reaction was performed using spe-
ciﬁc primers for BRAF, GNAQ, and GNA11 (Table 1).
PCR parameters were as follows: denaturation for 5 min
at 95 C; 35 cycles of 1 min at 95 C; annealing for 1 min at56–60 C and for 1 min at 72 C with Taq polymerase. The PCR
product was ampliﬁed on 2% agarose gel and visualized with ethi-
dium bromide staining. Direct sequencing of the PCR products was
performed with reagents and an analyzer (Big Dye Terminator Cy-
cle Sequencing and ABI PRISM 3700 DNA Analyzer; Applied Biosys-
tems, Foster City, CA).
4.5. Copy number analysis
For quantitative detection of the BRAF gene, the relative dosage
was determined using an ABI 7500 real-time PCR system (Applied
Biosystems). The 15-l reaction mixture contained FAM-labeled 1x
TaqMan BRAF kit (ABI, Hs05004157_CN), VIC-labeled 1x
TaqMan Human RNase P detection mix (ABI, Cat. No.
431684906018), 1x TaqMan Universal PCR Master Mix (AmpliTaq
Gold DNA Polymerase, dNTPs with dUTP, Passive Reference, No
AmpErase UNG), and 5 ng genomic DNA template. RNaseP, a sin-
gle-copy gene, was used as an endogenous control. Molecules of
the two genes were independently ampliﬁed. FAM and VIC signals
were recorded in all chambers at the end of each PCR cycle. Multi-
plex PCRs were undertaken using 20-ll reactions: 10 ll PCR Mas-
ter Mix (TaqMan Universal; Applied Biosystems) with 1 ll uracil N-
glycosylase, 1 ll RNaseP primers and probe 20 (VIC), 4 ll BRAF
primers and probe 20 (FAM), 4 ll of the DNA sample, and 4 ll
nuclease-free water. The default setting was selected for one cycle
at 95 C for 10 min, followed by 40 cycles at 95 C for 15 s and
annealing-extension at 60 C for 1 min. Each sample was tested
in Triplicates, with no-template controls in each assay. After the
reaction was completed, digital PCR analysis software (CopyCal-
lerTM, Applied Biosystems) was used to process the data and count
the numbers of both FAM-positive chambers (BRAF, target gene)
and VIC-positive chambers (RNaseP) in each panel. A total of 47
samples were analyzed, one sample (no. 32) failed technically
due to limited amount of DNA.4.6. Statistical analysis
The Statistical Package for the Social Sciences (SPSS), version 15,
was used for data analysis. Means and standard deviations were
calculated for all continuous variables. Chi-square test and Fisher
exact test were used to determine differences in distribution across
categorical variables or between two groups for continuous vari-
ables, respectively. The level of signiﬁcance was set at P < 0.05
for all statistical analyses.Acknowledgments
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